reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
It is perfectly legitimate to write [H+] for the hydronium ion concentration, since the state of solvation of the proton is constant (in dilute solutions) and so does not affect the equilibrium concentrations. Kw varies with variation in ionic strength and/or temperature. The concentrations of H+ and OH− are not independent quantities. Most commonly [OH−] is replaced by Kw[H+]−1 in equilibrium constant expressions which would otherwise include hydroxide ion. Solids also do not appear in the equilibrium constant expression, if they are considered to be pure and thus their activities taken to be one. An example is the Boudouard reaction:
In humans, 24 copies of E2 arranged in octahedral symmetry form the core of the BCKDC. Non-covalently linked to this polymer of 24 E2 subunits are 12 E1 α2β2 tetramers and 6 E3 homodimers. In addition to the E1/E3-binding domain, there are 2 other important structural domains in the E2 subunit: (i) a lipoyl-bearing domain in the amino-terminal portion of the protein and (ii) an inner-core domain in the carboxy-terminal portion. The inner-core domain is linked to the other two domains of the E2 subunit by two interdomain segments (linkers). The inner-core domain is necessary to form the oligomeric core of the enzyme complex and catalyzes the acyltransferase reaction (shown in the "Mechanism" section below). The lipoyl domain of E2 is free to swing between the active sites of the E1, E2, and E3 subunits on the assembled BCKDC by virtue of the conformational flexibility of the aforementioned linkers (see Figure 2). Thus, in terms of function as well as structure, the E2 component plays a central role in the overall reaction catalyzed by the BCKDC.
Newsom's first political experience came when he volunteered for Willie Brown's successful campaign for mayor in 1995. Newsom hosted a private fundraiser at his PlumpJack Café. Brown appointed Newsom to a vacant seat on the Parking and Traffic Commission in 1996, and he was later elected president of the commission. Brown appointed him to the San Francisco Board of Supervisors seat vacated by Kevin Shelley in 1997. At the time, he was the youngest member of San Francisco's board of supervisors. Newsom was sworn in by his father and pledged to bring his business experience to the board. Brown called Newsom "part of the future generation of leaders of this great city". Newsom described himself as a "social liberal and a fiscal watchdog". He was elected to a full four-year term to the board in 1998. San Francisco voters chose to abandon at-large elections to the board for the previous district system in 1999. Newsom was reelected in 2000 and 2002 to represent the second district, which includes Pacific Heights, the Marina, Cow Hollow, Sea Cliff, and Laurel Heights, which had San Francisco's highest income level and highest Republican registration. Newsom paid $500 to the San Francisco Republican Party to appear on the party's endorsement slate in 2000 while running for Supervisor. He was reelected. As a San Francisco Supervisor, Newsom gained public attention for his role in advocating reform of the city's municipal railway (Muni). He was one of two supervisors endorsed by Rescue Muni, a transit riders group, in his 1998 reelection.
The pelB leader sequence is a sequence of amino acids which, when attached to a protein, directs the protein to the bacterial periplasm, where the sequence is removed by a signal peptidase. Specifically, pelB refers to pectate lyase B of Erwinia carotovora CE. The leader sequence consists of the 22 N-terminal amino acid residues. This leader sequence can be attached to any other protein (on the DNA level) resulting in a transfer of such a fused protein to the periplasmic space of Gram-negative bacteria, such as Escherichia coli, often used in genetic engineering. Protein secretion can increase the stability of cloned gene products. For instance it was shown that the half-life of the recombinant proinsulin is increased 10-fold when the protein is secreted to the periplasmic space. (vijji. Narne, R.S.Ramya) One of pelB's possible applications is to direct coat protein-antigen fusions to the cell surface for the construction of engineered bacteriophages for the purpose of phage display. The Pectobacterium carotovorum pelB leader sequence commonly used in molecular biology has the sequence MKYLLPTAAAGLLLLAAQPAMA (UniProt Q04085).
The mendelevium separated by this method has the advantage of being free of organic complexing agent compared to the resin column; the disadvantage is that mendelevium then elutes very late in the elution sequence, after fermium. Another method to isolate mendelevium exploits the distinct elution properties of Md2+ from those of Es3+ and Fm3+. The initial steps are the same as above, and employs HDEHP for extraction chromatography, but coprecipitates the mendelevium with terbium fluoride instead of lanthanum fluoride. Then, 50 mg of chromium is added to the mendelevium to reduce it to the +2 state in 0.1 M hydrochloric acid with zinc or mercury. The solvent extraction then proceeds, and while the trivalent and tetravalent lanthanides and actinides remain on the column, mendelevium(II) does not and stays in the hydrochloric acid. It is then reoxidized to the +3 state using hydrogen peroxide and then isolated by selective elution with 2 M hydrochloric acid (to remove impurities, including chromium) and finally 6 M hydrochloric acid (to remove the mendelevium). It is also possible to use a column of cationite and zinc amalgam, using 1 M hydrochloric acid as an eluant, to effect the reduction. Thermochromatographic chemical isolation could be achieved using the volatile mendelevium hexafluoroacetylacetonate: the analogous fermium compound is known and similar.
Sources: en.wikipedia.org
Lately Executive Director, City Building. For services to Equality and Inclusion in Construction. Dr. Shriti Pattani. Lately President, The Society of Occupational Medicine. For services to Occupational Health. Nicola Heather Anne Patterson. Lately Director of Nursing, South Eastern Health and Social Care Trust. For services to Health and Social Care in Northern Ireland. Professor Rupert Mark Pearse. Professor of Intensive Care Medicine, Queen Mary University of London. For services to Intensive Care Medicine. Amy Sarah Perrin. Founder, The Marmalade Trust. For services to Older People. Oscar Victor Pinto-Hervia. Founder, Hervia. For services to Fashion and to Charity. Dr. Madsen Pirie. President, Adam Smith Institute. For services to Public Policy. Mary Margaret Portas. Retail Consultant and Broadcaster. For services to Business, to Broadcasting and to Charity. Alexander Reedijk. General Director, Scottish Opera. For services to the Performing Arts in Scotland. Marvin Rees. Mayor, Bristol City Council. For services to Local Government. Professor Julian Daryl Richards. Professor of Archaeology, University of York. For services to Heritage and Digital Archiving. Julian Richmond-Watson. Chair, Thoroughbred Breeders Association. For services to the British Horseracing Industry. José Salvador Riera. Deputy Director, Communications, Department for Culture, Media and Sport. For Public Service. Martin John Rigley, MBE. Lately Managing Director, Lindhurst Engineering Ltd. For services to the East Midlands Covid-19 Response and to the community in Derbyshire and Nottinghamshire.
== Accrediting organizations == For CLIA laboratories licensed under a Certificate of Accreditation (CoA), bi-annual inspections are conducted by a third-party accreditation organization (AO) that meets or exceeds the CLIA requirements. Though the Foundation for the Accreditation of Cellular Therapy (FACT) (formerly the Foundation for Accreditation of Hematopoietic Cell Transplantation) does not have deeming status under CLIA, most laboratories involved in cell therapies are accredited by FACT. In Dec 2022, TJC announced it would no longer recognize the Commission on Office Laboratory Accreditation (COLA) for lab accreditation at TJC hospitals, effective Jan 1, 2023, and facilities would have until Dec 31, 2024, to transition their accreditation. With the COVID-driven inspection backlog and a lack of inspectors, the move was criticized as being purely a financially driven attempt to capture additional market share. No reason for the change was given by CLIA, COLA, or TJC. TJC began recognizing COLA accreditation in 1997.
The fluorenylmethoxycarbonyl protecting group (Fmoc) is a base-labile amine protecting group used in organic synthesis, particularly in peptide synthesis. It is popular for its stability toward acids and hydrolysis and its selective removal by weak bases, such as piperidine, without affecting most other protecting groups or sensitive functional groups. Fmoc protection is especially advantageous in solid-phase peptide synthesis (SPPS), where its compatibility with other reagents and ease of removal streamline synthesis workflows. Upon deprotection, Fmoc yields a byproduct (Dibenzofulvene) that can be monitored by UV spectroscopy, allowing for efficient reaction tracking.
Eutyrannosaurs have a rough texture on their nasal bones and their mandibular fenestra is reduced externally. Tyrannosaurids lack kinetic skulls or special crests on their nasal bones, and have a lacrimal with a distinctive process on it. Tyrannosaurids also have an interfenestral strut that is less than half as big as the maxillary fenestra. Many phylogenetic analyses have found Tarbosaurus bataar to be the sister taxon of T. rex. The discovery of the tyrannosaurid Lythronax further indicates that Tarbosaurus and Tyrannosaurus are closely related, forming a clade with fellow Asian tyrannosaurid Zhuchengtyrannus, with Lythronax being their sister taxon. A further study from 2016 by Steve Brusatte, Thomas Carr and colleagues, also indicates that Tyrannosaurus may have been an immigrant from Asia, as well as a possible descendant of Tarbosaurus. This cladogram of Tyrannosauridae is based on the phylogenetic analysis conducted by Loewen and colleagues in 2013.
== Other animals == In dogs, OI is an autosomal recessive condition, meaning that dogs with two copies of the allele will be affected. Many breed organizations and veterinarians offer OI tests to tell if a dog is a carrier of OI. To prevent OI, dogs who are heterozygous for OI should not be bred. Naturally occurring mutations causing OI have been found in Golden Retrievers, Dachshunds, and Beagles. OI has also been identified in zebrafish and mice. Although dogs, mice, fish, and humans are not genetically identical, some of these animal models have been officially recognized to represent the varying types of OI in humans. For example, homozygous oim/oim mice experience spontaneous bone fractures, small body size, and kyphosis, making them a model of OI type III. Meanwhile, heterozygous oim/+ mice appear normal but have bones which are quite a bit weaker than wild mice, making them a model for OI type I. As in human OI, the location on the gene which is mutated affects the severity of resulting disease—the G859C Col1a1 mouse is a model for OI type II as affected mice all die in the perinatal period. Animal testing on identified animal models may lead to human therapies for OI.
Sources: en.wikipedia.org
=== Recreational use === Phenibut is used recreationally due to its ability to produce euphoria, anxiolysis, and increased sociability, as well as remaining undetected in routine urinalysis. Because of its delayed onset of effects, first-time users often mistakenly take an additional dose of phenibut in the belief that the initial dose did not work. Recreational users usually take the drug orally; there are a few case reports of rectal administration and one report of insufflation, which was described as "very painful" and causing swollen nostrils.
=== Pharmacodynamics === Benzodiazepine like compounds are acting as positive allosteric modulators to the gamma-aminobutyric acid GABAA receptor. GABA is the main inhibitor of neurotransmitters in the brain and modulates the activity of many neurons. Benzodiazepines bind to the GABAA receptor inducing a conformational change leading to an increased affinity to GABA. The allosteric binding site is situated in a "pocket" created by the alpha and gamma subunits. The pharmacological effects on benzodiazepines vary based on which alpha subunit of the GABAA receptor the benzodiazepine binds to. The sedative, anterograde amnesic, anticonvulsant actions, and the addictive nature of benzodiazepines, are due to the binding to the α1 subunit of the (GABA)A receptor. Binding to the α2 subunit will cause the anxiolytic effects, and binding to the α2, α3, and α5 subunits will lead to the myorelaxant effects. According to research done by the WHO bromazolam binds to the α1, α2, and α5 subunits.
14 August – Police are investigating the deaths of two 18-year-olds who attended an event at Glasgow's SWG3 venue. 16 August – Junior doctors in Scotland have voted to accept a pay offer from the Scottish Government worth 4.5% for 2022–23 and 12.4% for 2023–24. 17 August – GMB Scotland announces that non-teaching staff in ten Scottish council areas will stage two days of strike action on 13 and 14 September. The Scottish Parliament plays host to Comedy Unleashed, starring Father Ted creator Graham Linehan, after the show is cancelled by two venues in Edinburgh. Carnbooth House, a listed building and former hotel in Glasgow, is destroyed by fire. 22 August – Broadcaster Nicky Campbell gives evidence to the Scottish Child Abuse Inquiry, where he alleges that a teacher who worked at two Edinburgh schools abused children on a "Savile scale". 23 August – Murray Foote is appointed as the SNP's new chief executive, replacing Peter Murrell. 25 August – Alexander McKellar, who killed a cyclist on a remote road in the Scottish Highlands while drink driving in September 2017 and then hid the body, is sentenced to 12 years in prison. Members of Unison in 24 of Scotland's 32 council areas vote to take industrial action after rejecting a 5.5% pay offer. 26 August – A search for the Loch Ness Monster, described as the largest in 50 years, gets underway both in the vicinity of Loch Ness itself, and through an online stream of the loch. A group of people looking for the creature subsequently claim to have heard sounds, but fail to record anything.
=== Food additive === Silica gel, also referred to as silicon dioxide or synthetic amorphous silica (SAS), is listed by the FDA in the United States as generally recognized as safe (GRAS), meaning it can be added to food products without needing approval. Silica is allowed to be added to food in the US at up to 2% as permitted under 21 CFR 172.480. In the EU, it can be in up to 5% concentrations. In 2018, a re-evaluation by the EFSA Panel on Food Additives and Nutrient Sources added to Food found no indications of toxicity even at the highest estimates of exposure level. Listed uses include: anticaking agent, defoaming agent, stabilizer, adsorbent, carrier, conditioning agent, chill proofing agent, filter aid, emulsifying agent, viscosity control agent, and anti-settling agent. Silica can be found commonly in foods including baked goods, spices and herbs, dairy products, cocoa products, and more.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.